Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-23
DOI
10.1186/s40425-019-0767-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
- (2018) Jae H Park et al. CLINICAL INFECTIOUS DISEASES
- Effects of cryopreservation on chimeric antigen receptor T cell functions
- (2018) Hao Xu et al. CRYOBIOLOGY
- Influence of various medium environment to in vitro human T cell culture
- (2018) Hao Xu et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval
- (2018) Mark B. Geyer CLINICAL CANCER RESEARCH
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding cytokine release syndrome
- (2017) Philipp Gödel et al. INTENSIVE CARE MEDICINE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Diagnosis of Sepsis with Cell-free DNA by Next-Generation Sequencing Technology in ICU Patients
- (2016) Yun Long et al. ARCHIVES OF MEDICAL RESEARCH
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections
- (2016) Jeroen Slaats et al. PLoS Pathogens
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Inflammatory cytokine measurement quickly discriminates gram-negative from gram-positive bacteremia in pediatric hematology/oncology patients with septic shock
- (2012) Xiao-Jun Xu et al. INTENSIVE CARE MEDICINE
- Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification
- (2010) G. Tripepi et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search